Table 4 FINNAKI cohort. Quantification of NGAL isomers by Western blotting at admission to ICU
From: The origin of plasma neutrophil gelatinase-associated lipocalin in cardiac surgery
ALL (N = 61) | NO AKI (N = 26) | AKI ALL (N = 35) | AKI STAGE-1 (N = 13) | AKI STAGE 2 (N = 10) | AKI STAGE 3 (N = 12) | |
|---|---|---|---|---|---|---|
Monomeric, 25-kDa (%) | 0.9 (0.3–3.0) | 0.7 (0.4–1.5) | 0.9 (0.2–5.0) | 1.5 (0.2–7.0) | 0.7 (0.2–2.6) | 1.0 (0.4–3.9) |
Dimeric, 45-kDa (%) | 41.2 (33.3–53.1) | 45.4 (33.3–54.3) | 41.2 (33.2–51.3) | 41.1 (39.4–55.1) | 39.4 (33.1–49.0) | 41.2 (24.7–61.4) |
Hetero-dimeric, 145-kDa (%) | 53.5 (44.0–64.9) | 51.2 (42.6–66.4) | 53.8 (47.6–63.5) | 52.4 (42.1–58.9) | 56.6 (48.1–66.2) | 58.2 (36.0–70.7) |
NGAL at admission to ICU (ng/ml) | 51.2 (37.2–77.3) | 47.0 (35.3–79. 5) | 53.4 (38.2–63.8) | 57.0 (42.4–85.2) | 47.3 (20.5–55.2) | 54.0 (39.1–62.5) |
AKI Risk-score | 0.24 (0.16–0.41) | 0.17 (0.10–0.30) | 0.32** (0.18–0.47) | 0.24 (0.20–0.43) | 0.37 (0.19–0.49) | 0.29 (0.18–0.52) |